Lilly Faces India IP Challenges From Natco For Verzenio, Olumiant

Lilly’s anticancer abemaciclib and rheumatoid arthritis drug baricitinib, which has received a US EUA for COVID-19, have become targets of challenger Natco in India. The US giant says it's working closely with India’s health ministry to ensure access to patients who need its innovative therapies, amid indications Natco may be weighing plans to seek a voluntary license for baricitinib.